Oxford Biomedica plc
OXB.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 43.8% | -36% | -2% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 41.2% | 44.4% | 49.4% | 57.9% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | -£0 | -£0 | -£0 | £0 |
| % Margin | -30.6% | -205.7% | -21.6% | 14.5% |
| Other Income/Exp. Net | -£0 | -£0 | -£0 | -£0 |
| Pre-Tax Income | -£0 | -£0 | -£0 | £0 |
| Tax Expense | £0 | -£0 | -£0 | £0 |
| Net Income | -£0 | -£0 | -£0 | £0 |
| % Margin | -33.5% | -175.9% | -28% | 13.3% |
| EPS | -0.42 | -1.63 | -0.41 | 0.23 |
| % Growth | 74.2% | -297.6% | -278.3% | – |
| EPS Diluted | -0.42 | -1.63 | -0.41 | 0.22 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£0 | -£0 | -£0 | £0 |
| % Margin | -11.1% | -166% | -7.7% | 23.3% |